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Results: The median survival time was 1.82 years (95% CI – 1.57; 
2.06). A univariable analysis was performed for SUV descriptors and 
metabolic features. Results for the statistically significant metabolic 
features (p-value<0.05) are shown in Table 1. 
AVAI of 0.5 and 1, and AVRI of 10% showed a high correlation (Pearson 
correlation = 0.999,0.992 and 0.995) with GTV. 
Both RVRI of 80% and 90% (Pearson correlation =0.888) revealed a 
good prognostic value, outperforming the SUV descriptors. 
  
Conclusions: We investigated new approaches based on metabolic 
metrics derived from baseline PET images to analyze survival in NSCLC 
patients. AVAIof 0.5 and 1, and AVRI of 10% are a surrogate of tumor 
volume: highly correlated (≈1) with GTV and exhibiting identical 
performance. Metabolic features regarding portion of tumor above 
higher uptakes outperformed the most commonly used SUV metrics, 
maximum and mean. Currently, further investigation is ongoing by 
adding new patients to the analysis and applying results to an external 
dataset. 
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Purpose/Objective: SBRT for early stage non-small cell lung cancer is 
increasingly applied by many centres. Therefore, FDG-PET/CT is 
widely accepted as mandatory pre-treatment staging procedure, 
however, its timing is not standardised. In patients with locally 
advanced NSCLC, a high rate of tumou rgrowth and disease 
progression has been demonstrated when repeating the FDG-PET/CT 
during the SBRT planning phase accounting to about 30% upstaging 
probability within three weeks. The aim of this study was to 
investigate the FDG-PET/CT progression rate prior to SBRT. 
Materials and Methods: Nineteen consecutive early stage NSCLC 
patients referred for SBRT to the University Hospital Freiburg between 
08/2008 and 08/2011 were retrospectively analysed. All patients had 
already undergone an FDG-PET/CT scan at the time of referral and 
underwent a second FDG PET/CT for radiation planning purposes. All 
scans were analysed by two investigators blinded for treatment 
outcome regarding: availability of scan, tumour size and thus clinical 
T-stage, maximum standardized uptake value (SUVmax) in the tumour, 
additional FDG uptake in hilar/mediastinal lymph nodes (cN1/2) or at 
distant sites (cM1a/b). Progressive disease (>25% increase of tumour 
diameter on CT or >25% increase in SUVmax) and the time-interval 
between both imaging modalities were related to overall survival. 
Results: Median time interval between the diagnostic and planning 
FDG-PET/CT scan was 43 days (range: 22-140 days). After the planning 
FDG-PET/CT, 3/19 (15.8%) patients were not amenable for SBRT 
anymore due to diagnosis of nodal metastases (interscan interval: 22, 
51, and 95 days, respectively). No patients were found to have distant 
metastases. In the remaining 16 patients, no additional lesions were 
found, but one patient had progression in tumour diameter and two in 
SUVmax values. Notwithstanding, the lesions were still eligible for 
SBRT. Overall, upstaging occurred in 6/19 (31.6%) of patients, all but 
one with an interscan interval of more than 43 days (average 60 days, 
range 22-95 days). Overall, the upstaging probability with an interscan 
interval of less than 3 weeks was 0%. Furthermore, an SUVmax above 
median (9.50) on the diagnostic FDG-PET/CT scan was of borderline 
significance(p=0.06) for overall survival. 
Conclusions: In patients scheduled for SBRT, the rate of tumour 
growth and disease progression seen by repeated FDG-PET/CT was 
lower as compared to the situation in locally advanced disease. 
However, due to the risk of undertreatment of nodal progression in 
15.8% of cases, a timely scheduling of pre-treatment staging FDG-
PET/CT is recommended.  
 
 SYMPOSIUM: IMAGE-BASED ASSESSMENT OF THE 
RESPONSE OF NORMAL TISSUES TO RT  
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Radiation therapy (RT) is a major treatment modality for brain 
tumors.  As combining radiation therapy with chemotherapy and 
molecular targeted therapy is improving survival, neurotoxicity, 
including cognitive function decline and normal tissue necrosis, 
becomes an issue of quality of life.   Clinical symptoms and cognitive 
decline usually occur delayed or late as weeks, months or even years 
after the completion of RT. The clinical outcome ranges from mild, 
reversible damage to irreversible injury.  In the past, efforts to 
develop models to estimate the likelihood of developing radiation-
induced neurotoxicity have been primarily based on the planned 
radiation dose distribution, dose fraction size, and dose volume. 
These analyses have demonstrated their usefulness for permitting the 
safe delivery of higher doses of radiation than have previously been 
possible.  However, there is a broad range of individual patient 
sensitivity that is not reflected by predictions made solely based on 
the physical dose distribution or general clinical features.   If 
individual patient response to radiation could be better estimated 
before or during a course of treatment, it would permit higher doses 
of radiation to be delivered safely to the tumors of patients who is 
relatively radiation resistant, thus prolonging survival without 
increasing complications.   It would be valuable to identify 
biomarkers, including those derived from in vivo imaging, for early 
assessment of individual sensitivity to radiation and prediction of 
delayed and late neurotoxicity. Such biomarkers might provide an 
opportunity to individualize the dose of RT.  Our group has been 
conducting active research in this area.  We have used diffusion tensor 
(DTI) and dynamic contrast enhanced (DCE) MRI to assess individual 
and brain structural sensitivity to radiation.  Structural-variation in 
sensitivity to radiation may be related to the selective cognitive 
decline after brain irradiation.   Our results indicate that combining 
the early changes in the DTI and DCE indices of brain functional 
structures with doses has the potential to improve the prediction of 
delayed or late cognitive decline and/or brain tissue necrosis. 
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Radiation-induced lung toxicity (RILT) is one of the main dose-limiting 
factors in lung cancer treatment. It usually occurs within 3-6 months 
after the start of (chemo)radiotherapy and manifests itself with 
dyspnea, cough and fever. While the delivered dose to the lung is the 
primary cause of lung damage, different patients exhibit different 
susceptibility. In fact, only about 15%-25% of all lung cancer patients 
develop serious dyspnea problems (grade >=2 according to the 
Common Toxicity Criteria (CTC)), despite receiving a similar mean 
lung dose (15-20 Gy) as the rest of patients. It is therefore likely that 
other determinants, including clinical, dosimetric and tumor-related 
features, contribute to the observed individual susceptibility to lung 
damage. Since the heart and the lung form the interrelated 
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cardiopulmonary system, we hypothesize that the radiation dose 
delivered to the heart is likely to be an important contributor to the 
development of dyspnea, especially so in patients with cardiac 
comorbidity. Interestingly, while it has been shown that radiation to 
the heart increases the long-term risk of a cardiac event, insufficient 
research has been carried out on the short-term (3-6 months) effects 
of cardiac comorbidity and heart irradiation on the risk of 
radiotherapy-induced lung damage. Does the heart matter for RILT? 
Are there specific cardiac comorbidities associated with a higher 
probability of lung damage? Is there a short-term pulmonary effect 
from (excessive) heart irradiation? These research questions will be 
addressed in the talk, and recent promising evidence on this topic will 
be discussed. 
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Compared to 3D conformal radiotherapy (3DCRT), the advent of 
intensity modulated Radiotherapy (IMRT) for head andneck cancer 
patients (HNC) gave the possibility to dramatically reduce the dose to 
non-involved structures, and this is reported to be correlated to a 
reduced toxicity suffered by the patient. Nevertheless, even with 
IMRT, different toxicities continue to affect the quality of life of HNC 
patients after RT, being xerostomia and dysphagia two of the most 
important. In this context, it could be of particular interest the 
assessment of parameters able to predict individual patient tissue 
reactions during the treatment and possibly the risk of 
developingacute and/or late toxicity. This information could be used 
in order to select patients that may gain advantages by the 
implementation of personalized adaptive treatments and/or 
supportive therapies with the aim of reducing toxicity. 
Structural and volume variations of tissues/organs may be a sign of a 
radiation induced damage and could be measured using different 
image modalities. Image guided RT (IGRT) itself represents a powerful 
database of computed tomography (CT) images acquired during the 
treatment course, that in principle could be used to derive 
information regarding the tissues and organs reaction; also diagnostic 
CTs collected during the treatment for adaptive re-planning are 
another important source of available, high-quality CT information. 
Organs at risk (OAR) in HN region, such as parotid glands (PGs) or 
constrictor muscles, are known to undergo large volume and shape 
changes during RT treatments (that can be easily detected by CT-
images acquired during IGRT), and this is reported to be related to 
organ dysfunction. For example, PGs are known to shrink during HN 
treatment. In literature it is reported that the volume reduction at 
the end of therapy of 30-35 fractions/45 days is around 30-35%. 
On the other hand, density variation of organs during the treatment 
course may be considered as a surrogate of changes in tissue structure 
and therefore a potential measure of a radiation induced functional 
damage. Based on CT-images, it is possible to directly measure  
density variations in terms of Hounsfield units (HU) difference 
between images acquired during the treatment course. Focusing on 
PGs, recent hystopathological studies of tissue samples showed a 
reduction of the acinar cells number, with a relative increase of fat 
component in irradiated PGs compared to not irradiated, and this data 
is likely to be measured by CT-based density variation. Consistently, 
PGs density variation was found to vary significantly during the RT 
course in a large population of patients treated with IMRT; the largest 
variation was found during the first half part of the treatment 
compared to end (p-value=0.0001). Moreover, the early PGs 
density/volume variations, i.e.during the first two weeks of 
treatment, were found to be good predictors of the final changes at 
the end of the therapy (AUC>0.75, p-value=0.0001). Importantly, the 
median early PGs density variation resulted to be significantly 
different for a group of 25 patients with a prospectively assessed 
acute xerostomia score (CTC v3.0) during the treatment course. 
CT-based biomarkers assessed during the RT treatment course, such as 
volume, density and texture parameters, should be considered as 
promising scores which are likely to be surrogates of organ damage 
and consequently related to the probability risk to develop acute 
and/or late toxicity. 
  
 PROFFERED PAPERS: PHYSICS 7: INTRA-FRACTION 
MOTION MANAGEMENT  
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Purpose/Objective: Volumetric modulated arc therapy (VMAT) 
enables efficient delivery of highly conformal doses, but intrafraction 
tumor motion may lead to target dose distributions that differ 
markedly from the planned dose. The aim of this study was to 
measure the 3D target motion by continuous kV imaging during liver 
SBRT treatments delivered by VMAT and to reconstruct the actual 
target dose by use of the monitored motion. 
Materials and Methods: Five patients with liver metastasis and 2-3 
implanted gold markers received SBRT in three fractions of 18.75Gy or 
25Gy. The CTV was delineated on the mid-ventilation phase of a 4DCT 
scan. Margins of 5 mm in the axial plane and 10 mm in the sup-inf 
directions were added to form the PTV. A VMAT plan with 5-6 arcs was 
designed to give minimum target doses of 95% (CTV) and 67% (PTV). 
Abdominal compression was used for all patients. Daily cone-beam CT 
was used for marker based patient setup and continuous kV images 
(5Hz) and MV images (8-13 Hz) were acquired during treatment 
delivery with an On-Board Imager and an AS500 or AS1000 PortalVision 
system, respectively (Varian). Offline, the intra-treatment 3D 
trajectory of one gold marker was estimated from its projected 2D 
trajectory in the kV images by a probability based method. For three 
patients (those with coplanar arcs and high resolution MV imaging 
(AS1000)) the marker was segmented in all MV images with marker 
visibility at one fraction, which provided an independent measure of 
the kV 3D position estimation error. For all fractions the 3D marker 
motion was used to reconstruct the delivered target dose by a 
previously validated method that mimicks target motion by dividing 
the VMAT beams into sub-beams with different isocenter shifts and 
uses Eclipse (Varian) for dose calculation. The dose reconstruction 
included interplay effects and physical path length changes, but not 
target deformations or shifts relative to the gold marker. The 
reduction in D95 (minimum dose to 95% of the CTV) relative to the 
planned D95 was calculated for all fractions. 
 
 
Results: The gold marker was visible in all kV images and in 32% of the 
MV images. The MV images showed that the kV 3D position estimation 
had mean rms errors of 0.36 mm and 0.55 mm in the resolved and 
unresolved directions of the kV imager, respectively. Fig A shows the 
